<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01064505</url>
  </required_header>
  <id_info>
    <org_study_id>QRK.007</org_study_id>
    <nct_id>NCT01064505</nct_id>
  </id_info>
  <brief_title>Safety Study of a Single IVT Injection of QPI-1007 in Chronic Optic Nerve Atrophy and Recent Onset NAION Patients</brief_title>
  <official_title>A Phase I Open-Label, Dose Escalation Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Patients With Optic Nerve Atrophy (Stratum I) and Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) (Stratum II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Quark Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Quark Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where
      active study drug (QPI-1007) will be given to all patients who participate.

      This study will determine whether QPI-1007 is safe when it is injected into the eye. The
      study will also reveal if there are any side effects of the drug and how long it takes for
      the body to clear the drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be enrolled according to one of two sets of criteria designated as Stratum I
      and Stratum II.

        1. Stratum I will enroll Optic Nerve Atrophy patients who meet necessary criteria. Stratum
           I will consist of a maximum of 6 cohorts and each cohort will enroll 3 to 6 evaluable
           patients. Enrollment in Stratum I is now closed.

        2. Stratum II will enroll patients diagnosed with acute Non Arteritic Anterior Ischemic
           Optic Neuropathy (NAION) within 28 days of symptom onset who meet necessary criteria.
           Stratum II will consist of a maximum of 3 cohorts and each cohort will enroll up to 10
           evaluable patients. Enrollment in Stratum II is still open.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety, tolerability and the dose-limiting toxicities (DLTs) of QPI 1007 when administered as a single intravitreal (IVT) injection.</measure>
    <time_frame>12 Months Post-injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To assess the pharmacokinetics (PK) of QPI-1007 when administered as a single IVT injection.</measure>
    <time_frame>12 Months Post-Injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the presence of and to describe any anatomical changes in the optic nerve head and retina observed following the administration of a single IVT injection of QPI 1007.</measure>
    <time_frame>12 Months Post-Injection</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess any changes in visual acuity and visual field observed following the administration of a single IVT injection of QPI-1007.</measure>
    <time_frame>12 Months Post-Injection</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Optic Atrophy</condition>
  <condition>Non-arteritic Anterior Ischemic Optic Neuropathy</condition>
  <arm_group>
    <arm_group_label>QPI-1007</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>QPI-1007 at various doses</intervention_name>
    <description>Single Intravitreal Injection</description>
    <arm_group_label>QPI-1007</arm_group_label>
    <other_name>QPI-1007</other_name>
    <other_name>siRNA</other_name>
    <other_name>small interfering RNA</other_name>
    <other_name>short interfering RNA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Stratum I (Chronic Optic Nerve Atrophy) Inclusion Criteria:

          -  &quot;Legally blind&quot; in the study eye as the result of an irreversible condition affecting
             the posterior segment of the eye.

          -  Clear ocular media and able to undergo adequate pupil dilation.

          -  Visual acuity and visual field in the non-study eye are better than or equal to the
             study eye

          -  At least 21 years old.

        Key Stratum I (Chronic Optic Nerve Atrophy) Exclusion Criteria:

          -  For the study eye only: history of any IVT injection or vitrectomy, vitreous
             hemorrhage, retinal detachment, or active inflammatory condition (e.g.
             conjunctivitis).

          -  For either eye: history of uveitis.

        Enrollment is now closed in Stratum I.

        Key Stratum II (Acute NAION) Inclusion Criteria:

          -  Positive diagnosis of NAION with symptom onset within 28 days prior to planned dosing
             with QPI-1007.

          -  Visual acuity in the study eye is between 20/40 and light perception.

          -  Clear ocular media and able to undergo adequate pupil dilation.

          -  At least 50 years old.

        Key Stratum II (Acute NAION) Exclusion Criteria:

          -  For the study eye only: Macular disease, retinopathy, or other eye disease limiting
             visual acuity; prior intraocular surgery (other than Lasik) and cataract surgery
             within 3 months prior to dosing; glaucoma laser surgery within 1 month prior to
             dosing; pain on or aggravated by eye movement; history of vitreous hemorrhage; history
             of retinal detachment; any active inflammatory condition (e.g. conjunctivitis);
             glaucoma or ocular hypertension; or intraocular pressure &gt; 26 mmHg.

          -  For either eye: History of optic neuritis; or history of uveitis.

          -  Received any treatment for NAION prior to dosing.

          -  Any other abnormality which in the opinion of the investigator is suggestive of a
             disease other than NAION in the study eye only.

          -  Clinical evidence of temporal arteritis.

          -  History of collagen vascular disease or other inflammatory disease, or history of
             multiple sclerosis.

        Enrollment in Stratum II is still open.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rabia Ozden, MD</last_name>
    <role>Study Director</role>
    <affiliation>Quark Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Associates Medical Group</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jules Stein Eye Institute, University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer at the University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago, Eye and Ear Infirmary</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas University Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky, Department of Ophthalmology</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, Department of Ophthalmology</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mason Eye Institute, University of Missouri</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Eye and Ear Infirmary</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Flaum Eye Institute, University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye, Ear, Nose and Throat Associates, PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center, Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cole Eye Institute, Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Department of Ophthalmology</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny Ophthalmic and Orbital Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alkek Eye Center Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John A. Moran Eye Center at the University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soroka University Medical Center, Dept of Ophthalmology</name>
      <address>
        <city>Beer-Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bnai Zion Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>33394</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center, Belinson Campus, Dept of Ophthalmology</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center, Department of Ophthalmology</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Tel-Aviv Sourasky Medical Center, Dept of Ophthalmology</name>
      <address>
        <city>Tel-Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center, Dept of Ophthalmology</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 4, 2010</study_first_submitted>
  <study_first_submitted_qc>February 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2010</study_first_posted>
  <last_update_submitted>May 9, 2013</last_update_submitted>
  <last_update_submitted_qc>May 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ocular Neuroprotection</keyword>
  <keyword>ocular neuroprotectant</keyword>
  <keyword>NAION</keyword>
  <keyword>NAAION</keyword>
  <keyword>Non-arteritic ischemic optic neuropathy</keyword>
  <keyword>Non-arteritic anterior ischemic optic neuropathy</keyword>
  <keyword>chronic optic nerve atrophy</keyword>
  <keyword>optic nerve atrophy</keyword>
  <keyword>retinal degeneration</keyword>
  <keyword>optic neuritis</keyword>
  <keyword>end stage glaucoma</keyword>
  <keyword>Leber's hereditary optic neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Optic Nerve Diseases</mesh_term>
    <mesh_term>Optic Neuropathy, Ischemic</mesh_term>
    <mesh_term>Optic Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

